Available option
5mg / 1.2mL
Staff-prepared solution
- Strength
- 5mg / 1.2mL
- Format
- Staff-prepared solution
Bear Biotech catalogue
CJC-1295 (No DAC)
Short-acting modified GHRH/GRF research material
- GHRH receptor
- Pituitary signalling
- Sequence identity
Available presentations
Choose a strength and format
Each available presentation is listed separately. Current prices are confirmed from the Bear Biotech catalogue.
Available option
10mg / 1.2mL
Staff-prepared solution
- Strength
- 10mg / 1.2mL
- Format
- Staff-prepared solution
Available option
10mg
Lyophilised powder
- Strength
- 10mg
- Format
- Lyophilised powder
Research overview
What is CJC-1295 (No DAC)?
CJC-1295 No DAC is studied as a short-acting modified GHRH/GRF research material for investigating pituitary growth-hormone signalling and pulse dynamics. Interest centres on how short-duration GHRH-receptor stimulation differs from longer-acting DAC-conjugated compounds. Commercial naming is inconsistent, so exact sequence and lot identity remain important.
Commercial identity is ambiguous; related human endocrine research exists
Research focus
Key research areas
CJC-1295 No DAC research: short-acting GHRH signalling
CJC-1295 No DAC commonly describes a short-acting modified growth-hormone-releasing-factor material. It must remain distinct from albumin-binding CJC-1295 with DAC in human endocrine literature. Published findings concern defined experimental materials and do not establish the identity, quality, safety, efficacy or equivalence of Bear Biotech catalogue material.
- GHRH receptor
- Pituitary signalling
- Sequence identity
Representative primary research
Representative research
The closest primary CJC-1295 paper concerns the long-acting DAC, albumin-binding analogue, not the commercial No DAC designation.
- hGRF1-29-albumin bioconjugates activate the GRF receptor: identification of CJC-1295 ↗ Contextual reference only; it does not establish the sequence or identity of CJC-1295 No DAC.
These sources provide research context only. They do not verify the identity, quality or equivalence of a Bear Biotech catalogue batch; the matched lot-specific batch record remains controlling.
Specifications
Product information
- Material identity
- CJC-1295 (No DAC)
- Research category
- Short-acting modified GHRH/GRF research material
- Evidence position
- Commercial identity is ambiguous; related human endocrine research exists
- Recorded formats
- Staff-prepared solution · Lyophilised powder
- Batch-record basis
- The matched lot-specific record controls identity and analytical claims.
- Intended use
- Controlled laboratory research only.
Research questions
Evidence and identity questions
Why is the No DAC qualifier essential to CJC-1295 research?
CJC-1295 (No DAC) research examines short-acting GHRH-receptor signalling and downstream pituitary responses. The No DAC identity must remain distinct from long-acting CJC-1295 with DAC.
How does sequence identity affect short-acting GHRH study design?
Sequence identity determines whether a study concerns modified GRF(1-29), another GHRH analogue or CJC-1295 with DAC. Those materials can differ in persistence and study design.
What limits comparisons across materials sold as CJC-1295 No DAC?
Related human endocrine research exists, but the commercial identity called CJC-1295 (No DAC) is not always described consistently. Conclusions require verified sequence and cannot assume equivalence across suppliers.
Batch documentation
Lot-specific records stay connected to the order
Eligible lot-specific documentation may be viewed or requested from the registered Bear Biotech account when available for the applicable order.
Open Bear Biotech accountResearch use only
Controlled laboratory research material
Not for human or veterinary consumption. Administration, dosing and therapeutic guidance are not provided.